SHR-4610

SHR-4610 is an investigational biological anti-tumor drug being developed as an injectable therapy for patients with advanced solid tumors. It is described by its sponsor as an innovative oncology agent that has demonstrated promising anti-tumor activity in preclinical animal models and is now entering first-in-human, open-label, multicenter phase I/II clinical evaluation focused on dose exploration, safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy in a broad range of advanced malignant solid neoplasms.[3][5][8][9][11][13][15][16] Publicly available sources to date do not disclose its precise molecular modality, target, or detailed mechanism of action, but classify it generally as a biological product in oncology.[3]

Other names

SHR-4610 injectionSHR4610 injectionSHR 4610 injection